Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Gross Margin (2016 - 2025)

Historic Gross Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 58.38%.

  • Harvard Bioscience's Gross Margin rose 2800.0% to 58.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.94%, marking a year-over-year decrease of 14600.0%. This contributed to the annual value of 58.18% for FY2024, which is 6800.0% down from last year.
  • As of Q3 2025, Harvard Bioscience's Gross Margin stood at 58.38%, which was up 2800.0% from 56.4% recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Gross Margin peaked at 61.2% during Q1 2023, and registered a low of 45.21% during Q3 2022.
  • Over the past 5 years, Harvard Bioscience's median Gross Margin value was 57.18% (recorded in 2021), while the average stood at 56.84%.
  • In the last 5 years, Harvard Bioscience's Gross Margin plummeted by -97700bps in 2022 and then soared by 128500bps in 2023.
  • Over the past 5 years, Harvard Bioscience's Gross Margin (Quarter) stood at 59.17% in 2021, then fell by -6bps to 55.7% in 2022, then rose by 4bps to 57.99% in 2023, then decreased by -2bps to 57.06% in 2024, then rose by 2bps to 58.38% in 2025.
  • Its Gross Margin stands at 58.38% for Q3 2025, versus 56.4% for Q2 2025 and 55.96% for Q1 2025.